Create an Account
  1. Home
  2. Specialty
  3. Retina

New Paradigms in the Management and Treatment of Diabetic Macular Edema (March 2016)

New Paradigms in the Management and Treatment of Diabetic Macular Edema March 2016
Program Information
Take Pre-Test

The live program has concluded.


If you attended, please click on the "Take Post-Test" button to claim your credit. If you did not attend, please stay tuned for the archived version, which will be available soon for on-demand viewing.

Scroll back to top
Details

  • Overview

    Diabetes mellitus (diabetes) is a growing worldwide epidemic, affecting largely a working age population. By 2035, it is estimated to affect nearly 600 million people worldwide will be living with diabetes, a marked increase from the 382 million in 2013. Patients with diabetes are at an increased risk of several morbid and chronic conditions, among them acute coronary syndrome, hypertension, and retinopathy.Supported by an educational grant from Alimera Sciences.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to: • Describe the current epidemiology of diabetic macular edema and diabetic retinopathy • Educate patients on the ophthalmic implications of systemic diabetes management • Assess clinical studies involving new approaches to treat DME • Use expert case examples to differentiate between clinical study dosing protocols and alternative dosing schedules • Evaluate treatment options and develop a treatment regimen that can reduce patient burden and practice capacity • Explain the early warning signs of elevated IOP • Identify effective management strategies for patients requiring intervention

  • Accreditation

    Accreditation Statement

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education and Retina Today.

     

    Credit Designation Statement

    Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Grantor Statement

    This continuing medical education activity is supported through an educational grant from Alimera Sciences.

  • Participation Method

    Participants should read the CME activity in its entirety. After reviewing the material, please complete the self-assessment test, which consists of a series of multiple-choice questions. To answer these questions online and receive real-time results, please visit evolvemeded.com and click “Online Courses.” Upon completing the activity and achieving a passing score of greater than 70% on the self-assessment test, you may print a CME credit letter awarding 1 AMA PRA Category 1 Credit.TM The estimated time to complete this activity is 1 hour.

  • Faculty and Disclosures

    DISCLOSURE POLICY
    It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

    Pravin U. Dugel, MD Retinal Consultants of Arizona Phoenix, Arizona

    Alexander Eaton, MD Retina Health Center Fort Meyers, Florida

    Nancy Holekamp, MD Pepose Vision Institute St. Louis, Missouri

    Szilard Kiss, MD Weill Cornell Medicine New York, New York

    Baruch D. Kupperman, MD, PhD UC Irvine Health Gavin Herbert Eye Institute Irvine, California

    Nathan Radcliffe, MD Glaucoma Service NYU Langone Ophthalmology Associates New York, New York

    It is the policy of Evolve Medical Education LLC that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve Medical Education LLC has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity. The following faculty members have the following financial rela- tionships with commercial interests: Pravin U. Dugel, MD, has had a financial agreement or affiliation during the past year with the following: Consultant/ Advisory Board: Abbott Medical Optics; Aerpio Therapeutics: Alcon; Alimera Sciences; Allergan; Annidis; Acucela; ArticAx US Ltd.; Avalanche Biotechnologies; Clearside Biomedical; DigiSight; DOSE Medical; Genentech; Lutronic; Lux BioSciences; Novartis; OD-OS; Omeros; Ophthotech; Opthea Limited; Optuvue; ORA; Regeneron Pharmaceuticals; Roche Pharma; PentaVision LLC; Stealth BioTherapeutics; ThromboGenics; and Topcon Corporation. Stock Shareholder: Alimera Sciences; Aerpio Therapeutics; Annidis; DigiSight; Neurotech USA; Ophthotech; and TruVision. Alexander Eaton, MD, has had a financial agreement or affiliation during the past year with the following: Speaker’s Bureau: Alimera Sciences. Grant/Research Support: Alimera Sciences; Allergan; Genentech and Regeneron Pharmaceuticals. Stock Shareholder: Alimera Sciences and Regeneron Pharmaceuticals. Nancy M. Holekamp, MD, has had a financial agreement or affiliation during the past year with the following: Consultant/ Advisory Board: Alimera Sciences; Allergan; Katalyst; Ophthotech; and Regeneron Pharmaceuticals. Grant/Research Support: Alimera Sciences; Allergan; Neurotech Pharmaceuticals; and Ophthotech. Stock Shareholder: Katylst. Szilárd Kiss, MD, has had a financial agreement or affiliation during the past year with the following: Retained Consultant: Alimera Science; Allergan; Genentech; Regeneron Pharmaceuticals. Speakers Bureau: Alimera Science; Allergan; Genentech; Regeneron Pharmaceuticals. Baruch D. Kuppermann, MD, has had a financial agreement or affiliation during the past year with the following: Consultant/ Advisory Board: Aerpio Therapeutics; Alcon; Alimera Sciences; Allergan; Allegro Ophthalmics, LLC; Ampio Pharmaceuticals; DOSE Medical; Eleven Biotherapeutics; Genentech; GlaxoSmithKline; Glauxos Corporation; Lumenis; Neurotech Pharmaceuticals; Novartis; Ophthotech Corporation; Regeneron Pharmaceuticals; SecondSight Medical Products; and ThromboGenics. Grant/ Research Support: Alcon; Alimera Sciences; Allergan; Allegro Ophthalmics LLC; Ampio Pharmaceuticals; Apellis Pharmaceuticals; Genentech; GlaxoSmithKline; Neurotech Pharmaceuticals; Ophthotech Corporation; Regeneron Pharmaceuticals; and ThromboGenics. Nathan Radcliffe, MD, has had a financial agreement or affiliation during the past year with the following: Consultant/Advisory Board: Alimera Sciences; Allergan; ForSight Labs; Glaukos; Iridex, Lumenis; Reichert Technologies; and Vision 5.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve Medical Education LLC, New Retina MD, Retina Today or Alimera Sciences.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Expiration Date:

1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

LIVE ON REACHMD RADIOBack to live radio
ReachMD Radio

Loading...

00:00
00:00
    Register

    We're glad to see you're enjoying Evolve Medical Education…
    but how about a more personalized experience?

    Register for free